The immunology of tuberculosis: From bench to bedside
暂无分享,去创建一个
[1] Alimuddin Zumla,et al. Feasibility and Diagnostic Utility of Antigen-Specific Interferon-γ Responses for Rapid Immunodiagnosis of Tuberculosis Using Induced Sputum , 2010, PloS one.
[2] M. Pai. Spectrum of latent tuberculosis — existing tests cannot resolve the underlying phenotypes , 2010, Nature Reviews Microbiology.
[3] G. Kaplan,et al. Advances in immunotherapy for tuberculosis treatment. , 2009, Clinics in chest medicine.
[4] S. Choi,et al. Diagnosis of abdominal tuberculosis by T-cell-based assays on peripheral blood and peritoneal fluid mononuclear cells. , 2009, The Journal of infection.
[5] J. Casanova,et al. Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis , 2009, The Journal of experimental medicine.
[6] C. Weber,et al. Neutrophil granule proteins tune monocytic cell function. , 2009, Trends in immunology.
[7] J. Flynn,et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.
[8] R. Eberhardt,et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. , 2009, American journal of respiratory and critical care medicine.
[9] M. Veldhoen,et al. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. , 2009, Immunity.
[10] Mi‐jeong Kim,et al. Foamy macrophages and the progression of the human tuberculosis granuloma , 2009, Nature Immunology.
[11] S. Kaufmann,et al. Fine-tuning of T cell responses during infection. , 2009, Current opinion in immunology.
[12] G. Bjune,et al. The protective role of antibody responses during Mycobacterium tuberculosis infection , 2009, Clinical and experimental immunology.
[13] A. Diacon,et al. Differential cytokine/chemokines and KL-6 profiles in patients with different forms of tuberculosis. , 2009, Cytokine.
[14] S. Kaufmann,et al. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. , 2009, Vaccine.
[15] E. Bateman,et al. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis , 2009, Thorax.
[16] H. Bang,et al. Tuberculosis Is Associated with a Down-Modulatory Lung Immune Response That Impairs Th1-Type Immunity1 , 2009, The Journal of Immunology.
[17] B. Ryffel,et al. TLR2-dependent mast cell activation contributes to the control of Mycobacterium tuberculosis infection. , 2009, Microbes and infection.
[18] E. Bateman,et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. , 2009, American journal of respiratory and critical care medicine.
[19] P. Andersen,et al. Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.
[20] P. Saha,et al. FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. , 2009, American journal of respiratory and critical care medicine.
[21] R. Casetti,et al. Characterization of regulatory T cells identified as CD4+CD25highCD39+ in patients with active tuberculosis , 2009, Clinical and experimental immunology.
[22] M. Brennan,et al. Tuberculosis vaccine research: the impact of immunology. , 2009, Current opinion in immunology.
[23] R. Hussain,et al. Dynamic Changes in Biomarker Profiles Associated with Clinical and Subclinical Tuberculosis in a High Transmission Setting: A Four‐Year Follow‐Up Study , 2009, Scandinavian journal of immunology.
[24] C. Antoni,et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. , 2009, The Journal of clinical investigation.
[25] J. Dietrich,et al. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[26] M. Pai,et al. T-cell interferon-γ release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings , 2009, Current opinion in pulmonary medicine.
[27] Robert J Wilkinson,et al. Eliminating latent tuberculosis. , 2009, Trends in microbiology.
[28] Alimuddin Zumla,et al. Biomarkers for tuberculosis disease status and diagnosis , 2009, Current opinion in pulmonary medicine.
[29] F. Cobelens,et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement , 2009, European Respiratory Journal.
[30] E. Bateman,et al. Utility of quantitative T-cell responses versus unstimulated interferon-γ for the diagnosis of pleural tuberculosis , 2009, European Respiratory Journal.
[31] R. Liblau,et al. Invariant NKT cells inhibit development of the Th17 lineage , 2009, Proceedings of the National Academy of Sciences.
[32] G. Kaplan,et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. , 2009, The Journal of infectious diseases.
[33] A. Cooper,et al. Cell-mediated immune responses in tuberculosis. , 2009, Annual review of immunology.
[34] Sung Goo Park,et al. NADPH Oxidase 2 Interaction with TLR2 Is Required for Efficient Innate Immune Responses to Mycobacteria via Cathelicidin Expression1 , 2009, The Journal of Immunology.
[35] J. Chan,et al. How B cells shape the immune response against Mycobacterium tuberculosis , 2009, European journal of immunology.
[36] R. Wilkinson,et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. , 2009, The Journal of infectious diseases.
[37] P. Ravn,et al. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay , 2009, BMC Research Notes.
[38] R. Wallis. Mycobacterial disease attributable to tumor necrosis factor-alpha blockers. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] P. V. van Helden,et al. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis , 2008, Clinical and experimental immunology.
[40] R. Gie,et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[41] A. Chiba,et al. Innate Invariant NKT Cells Recognize Mycobacterium tuberculosis–Infected Macrophages, Produce Interferon-γ, and Kill Intracellular Bacteria , 2008, PLoS pathogens.
[42] V. M. Frolov,et al. Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin. , 2008, Cytokine.
[43] M. Behr,et al. NOD2-Deficient Mice Have Impaired Resistance to Mycobacterium tuberculosis Infection through Defective Innate and Adaptive Immunity1 , 2008, The Journal of Immunology.
[44] X. Zhan,et al. Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection. , 2008, Blood.
[45] M. Salmon,et al. The kinetics of CD4+Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. , 2008, The Journal of clinical investigation.
[46] T. Ottenhoff,et al. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. , 2008, Human immunology.
[47] P. Crivelli,et al. Clinical Usefulness of ELISPOT Assay on Pericardial Fluid in a Case of Suspected Tuberculous Pericarditis , 2008, Infection.
[48] A. Krarup,et al. Multiple routes of complement activation by Mycobacterium bovis BCG. , 2008, Molecular immunology.
[49] P. Méndez-Samperio. Role of antimicrobial peptides in host defense against mycobacterial infections , 2008, Peptides.
[50] S. Kaufmann,et al. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. , 2008, Cell host & microbe.
[51] R. Modlin,et al. Human macrophage host defense against Mycobacterium tuberculosis. , 2008, Current opinion in immunology.
[52] T. Ottenhoff,et al. Human Anti-Inflammatory Macrophages Induce Foxp3+GITR+CD25+ Regulatory T Cells, Which Suppress via Membrane-Bound TGFβ-11 , 2008, The Journal of Immunology.
[53] C. Leclerc,et al. Effect of Attenuation of Treg during BCG Immunization on Anti-Mycobacterial Th1 Responses and Protection against Mycobacterium tuberculosis , 2008, PloS one.
[54] A. Aseffa,et al. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. , 2008, Vaccine.
[55] D. Flower,et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination , 2008, Proceedings of the National Academy of Sciences.
[56] K. Chu,et al. Diagnosis of Central Nervous System Tuberculosis by T-Cell-Based Assays on Peripheral Blood and Cerebrospinal Fluid Mononuclear Cells , 2008, Clinical and Vaccine Immunology.
[57] U. Schaible,et al. Innate immunity in tuberculosis: myths and truth. , 2008, Microbes and infection.
[58] P. V. van Helden,et al. Differential Expression of Interleukin-4 (IL-4) and IL-4δ2 mRNA, but Not Transforming Growth Factor Beta (TGF-β), TGF-βRII, Foxp3, Gamma Interferon, T-bet, or GATA-3 mRNA, in Patients with Fast and Slow Responses to Antituberculosis Treatment , 2008, Clinical and Vaccine Immunology.
[59] Chang‐you Wu,et al. CD4+ CD25+ Treg cells inhibit human memory gammadelta T cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6. , 2008, Blood.
[60] G. Kutsyna,et al. Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. , 2008, International immunopharmacology.
[61] B. Marshall,et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[62] R. Casetti,et al. The Plasticity of γδ T Cells: Innate Immunity, Antigen Presentation and New Immunotherapy , 2008, Cellular and Molecular Immunology.
[63] P. Hopewell,et al. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.
[64] K. Higuchi,et al. Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.
[65] C. Bolliger,et al. Evaluation of Adapted Whole-Blood Interferon-γ Release Assays for the Diagnosis of Pleural Tuberculosis , 2008, Respiration.
[66] C. Senner,et al. Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.
[67] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[68] N. Langeland,et al. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON® TB-Gold interferon-gamma assay , 2008, BMC infectious diseases.
[69] N. Connell,et al. Natural killer cells, glutathione, cytokines, and innate immunity against Mycobacterium tuberculosis. , 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[70] G. Kaplan,et al. Bacillus Calmette-Guérin Vaccination of Human Newborns Induces T Cells with Complex Cytokine and Phenotypic Profiles1 , 2008, The Journal of Immunology.
[71] Limin Zheng,et al. Mycobacterium tuberculosis-induced apoptotic neutrophils trigger a pro-inflammatory response in macrophages through release of heat shock protein 72, acting in synergy with the bacteria. , 2008, Microbes and infection.
[72] G. Nicolardi,et al. Abdominopelvic tuberculosis in gynaecology: Laparoscopical and new laboratory findings , 2008, The Australian & New Zealand journal of obstetrics & gynaecology.
[73] Z. Toossi,et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study , 2008, BMC infectious diseases.
[74] M. Ernst,et al. Rapid Diagnosis of CNS Tuberculosis by a T-Cell Interferon-γ Release Assay on Cerebrospinal Fluid Mononuclear Cells , 2008, Infection.
[75] S. Kaufmann,et al. Rational design of vaccines against tuberculosis directed by basic immunology. , 2008, International journal of medical microbiology : IJMM.
[76] L. Fabbri,et al. Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy , 2007, European Respiratory Journal.
[77] C. Locht,et al. Heparin-Binding-Hemagglutinin-Induced IFN-γ Release as a Diagnostic Tool for Latent Tuberculosis , 2007, PloS one.
[78] T. Scriba,et al. Immunological protection against tuberculosis. , 2007, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[79] J. Keane,et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. , 2007, Immunity.
[80] A. Rudensky,et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis , 2007, The Journal of experimental medicine.
[81] F. Poccia,et al. Central Memory Vγ9Vδ2 T Lymphocytes Primed and Expanded by Bacillus Calmette-Guérin-Infected Dendritic Cells Kill Mycobacterial-Infected Monocytes1 , 2007, The Journal of Immunology.
[82] R. Modlin,et al. Cutting Edge: Vitamin D-Mediated Human Antimicrobial Activity against Mycobacterium tuberculosis Is Dependent on the Induction of Cathelicidin1 , 2007, The Journal of Immunology.
[83] G. Rook,et al. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? , 2007, The Journal of infectious diseases.
[84] R. Wilkinson,et al. Neutrophil-mediated innate immune resistance to mycobacteria. , 2007, The Journal of clinical investigation.
[85] A. Aderem,et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis , 2007, Genes and Immunity.
[86] B. D. de Jong,et al. Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis Infection , 2007, PLoS medicine.
[87] Armando Garsd,et al. Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS Patients , 2007, Antimicrobial Agents and Chemotherapy.
[88] S. Alonso,et al. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy , 2007, Proceedings of the National Academy of Sciences.
[89] R. Joshi,et al. Sensitivity of a Whole-Blood Interferon-Gamma Assay Among Patients with Pulmonary Tuberculosis and Variations in T-Cell Responses During Anti-Tuberculosis Treatment , 2007, Infection.
[90] P. Hopewell,et al. Messenger RNA Expression of IL-8, FOXP3, and IL-12β Differentiates Latent Tuberculosis Infection from Disease1 , 2007, The Journal of Immunology.
[91] S. Kaufmann,et al. Cutting Edge: Regulatory T Cells Prevent Efficient Clearance of Mycobacterium tuberculosis , 2007, The Journal of Immunology.
[92] A. Sher,et al. Cooperation of Toll-like receptor signals in innate immune defence , 2007, Nature Reviews Immunology.
[93] Z. Xing,et al. Gamma Interferon Responses of CD4 and CD8 T-Cell Subsets Are Quantitatively Different and Independent of Each Other during Pulmonary Mycobacterium bovis BCG Infection , 2007, Infection and Immunity.
[94] L. Cosmi,et al. Detection by Flow Cytometry of ESAT-6- and PPD-Specific Circulating CD4+ T Lymphocytes as a Diagnostic Tool for Tuberculosis , 2006, International Archives of Allergy and Immunology.
[95] Z. Toossi,et al. Intestinal helminth co‐infection has a negative impact on both anti‐Mycobacterium tuberculosis immunity and clinical response to tuberculosis therapy , 2006, Clinical and experimental immunology.
[96] Jennifer L. Martin,et al. Surfactant Protein D Increases Fusion of Mycobacterium tuberculosis- Containing Phagosomes with Lysosomes in Human Macrophages , 2006, Infection and Immunity.
[97] J. Deeks,et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. , 2006, American journal of respiratory and critical care medicine.
[98] V. Deretic,et al. Human IRGM Induces Autophagy to Eliminate Intracellular Mycobacteria , 2006, Science.
[99] L. Aarons,et al. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. , 2006, The Journal of antimicrobial chemotherapy.
[100] P. V. van Helden,et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders , 2006, Clinical and experimental immunology.
[101] R. Adegbola,et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. , 2006, The Lancet. Infectious diseases.
[102] R. Joshi,et al. Serial testing of health care workers for tuberculosis using interferon-γ assay , 2006 .
[103] S. Swain,et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection , 2006, The Journal of experimental medicine.
[104] H. Weiner,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.
[105] C. Locht,et al. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. , 2006, Tuberculosis.
[106] Alimuddin Zumla,et al. Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. , 2006, Tuberculosis.
[107] S. Kalantri,et al. New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis , 2006, Expert review of molecular diagnostics.
[108] J. Pieters. Faculty Opinions recommendation of Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. , 2006 .
[109] A. Lalvani,et al. Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. , 2006, American journal of respiratory and critical care medicine.
[110] Z. Toossi,et al. A role for CD4+CD25+ T cells in regulation of the immune response during human tuberculosis , 2006, Clinical and experimental immunology.
[111] R. Adegbola,et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases , 2006, BMC infectious diseases.
[112] J. Ellner,et al. Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. , 2006, American journal of respiratory and critical care medicine.
[113] B. Metchock,et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[114] D. Machin,et al. Early Clinical Trials , 2005 .
[115] Jean-Louis Herrmann,et al. DC-SIGN Induction in Alveolar Macrophages Defines Privileged Target Host Cells for Mycobacteria in Patients with Tuberculosis , 2005, PLoS medicine.
[116] J. Deeks,et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study , 2005, The Lancet.
[117] A. Azad,et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis , 2005, The Journal of experimental medicine.
[118] Alimuddin Zumla,et al. Lung remodeling in pulmonary tuberculosis. , 2005, The Journal of infectious diseases.
[119] S. Jolles,et al. Therapeutic Efficacy of High-Dose Intravenous Immunoglobulin in Mycobacterium tuberculosis Infection in Mice , 2005, Infection and Immunity.
[120] S. Kaufmann,et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.
[121] Alimuddin Zumla,et al. Immune responses to tuberculosis in developing countries: implications for new vaccines , 2005, Nature Reviews Immunology.
[122] M. Horwitz,et al. Enhancing the Protective Efficacy of Mycobacterium bovis BCG Vaccination against Tuberculosis by Boosting with the Mycobacterium tuberculosis Major Secretory Protein , 2005, Infection and Immunity.
[123] P. Andersen,et al. The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.
[124] A. Stryhn,et al. Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 1 , 2005, The Journal of Immunology.
[125] K. Dheda,et al. Utility of the antigen-specific interferon-γ assay for the management of tuberculosis , 2005, Current opinion in pulmonary medicine.
[126] Stefan H E Kaufmann,et al. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis , 2005, Nature Medicine.
[127] D. Lewinsohn,et al. Role of CD8+ T lymphocytes in control of Mycobacterium tuberculosis infection. , 2005, Microbes and infection.
[128] J. Ellner,et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. , 2005, The Journal of infectious diseases.
[129] Virginia Arcos,et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. , 2005, Vaccine.
[130] V. Deretic,et al. Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages , 2004, Cell.
[131] P. López-Saura,et al. Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study , 2004, BMC infectious diseases.
[132] M. Broder,et al. Granulomatous infections due to tumor necrosis factor blockade: correction. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[133] Z. Xing,et al. Activation of CD8 T Cells by Mycobacterial Vaccination Protects against Pulmonary Tuberculosis in the Absence of CD4 T Cells1 , 2004, The Journal of Immunology.
[134] K. Lee,et al. Six-month Therapy with Aerosolized Interferon-γ for Refractory Multidrug-Resistant Pulmonary Tuberculosis , 2004, Journal of Korean medical science.
[135] Matthijs Kramer,et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[136] M. Amicosante,et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[137] V. Deretic,et al. A tale of two lipids: Mycobacterium tuberculosis phagosome maturation arrest. , 2004, Current opinion in microbiology.
[138] John L. Johnson,et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.
[139] D. Guwatudde,et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. , 2003, American journal of epidemiology.
[140] Gregory A. Taylor,et al. Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47 , 2003, Science.
[141] Shigeru Matsukura,et al. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis , 2003, Respirology.
[142] S. Kaufmann,et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis , 2003, Nature Medicine.
[143] John L. Johnson,et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[144] T. Geijtenbeek,et al. Mycobacteria Target DC-SIGN to Suppress Dendritic Cell Function , 2003, The Journal of experimental medicine.
[145] O. Schwartz,et al. DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells , 2003, The Journal of experimental medicine.
[146] G. Dougan,et al. Chronic bacterial infections: living with unwanted guests , 2002, Nature Immunology.
[147] Alimuddin Zumla,et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial , 2002, The Lancet.
[148] R. Dietze,et al. Intestinal nematodes and pulmonary tuberculosis. , 2002, Revista da Sociedade Brasileira de Medicina Tropical.
[149] G. Rook,et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells , 2002, Nature Medicine.
[150] Naresh J. Patel,et al. Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. , 2002, Journal of the Indian Medical Association.
[151] John Gatfield,et al. Hijacking the host: survival of pathogenic mycobacteria inside macrophages. , 2002, Trends in microbiology.
[152] G. Trinchieri. Regulatory Role of T Cells Producing both Interferon γ and Interleukin 10 in Persistent Infection , 2001, The Journal of experimental medicine.
[153] P. Sonnenberg,et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers , 2001, The Lancet.
[154] J. Vekemans,et al. Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia , 2001, Infection and Immunity.
[155] S. Kaufmann,et al. How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.
[156] John Chan,et al. Tuberculosis: Latency and Reactivation , 2001, Infection and Immunity.
[157] P. Fine,et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy , 2001, Epidemiology and Infection.
[158] C. Immanuel,et al. Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[159] B. Petros,et al. Effect of deworming on human T cell responses to mycobacterial antigens in helminth‐exposed individuals before and after bacille Calmette–Guérin (BCG) vaccination , 2001, Clinical and experimental immunology.
[160] P. Fine. BCG: The Challenge Continues , 2001, Scandinavian journal of infectious diseases.
[161] M. Horwitz,et al. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[162] M. Bocchino,et al. Mycobacterium tuberculosis and HIV co-infection in the lung: synergic immune dysregulation leading to disease progression. , 2000, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[163] E. Arts,et al. Greater Diversity of HIV‐1 Quasispecies in HIV‐Infected Individuals With Active Tuberculosis , 2000, Journal of acquired immune deficiency syndromes.
[164] Z. Toossi,et al. Pulmonary Mononuclear Cell Responses to Antigens of Mycobacterium tuberculosis in Healthy Household Contacts of Patients with Active Tuberculosis and Healthy Controls from the Community1 2 , 2000, The Journal of Immunology.
[165] John L. Johnson,et al. Randomized Controlled Trial of Mycobacterium vaccae Immunotherapy in Non-Human Immunodeficiency Virus-Infected Ugandan Adults with Newly Diagnosed Pulmonary Tuberculosis , 2000 .
[166] Z. Toossi,et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. , 1999, The Journal of infectious diseases.
[167] M. Geletu,et al. T-Cell Recognition of Mycobacterium tuberculosisCulture Filtrate Fractions in Tuberculosis Patients and Their Household Contacts , 1999, Infection and Immunity.
[168] K. Moelling,et al. Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.
[169] Alimuddin Zumla,et al. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial , 1999, The Lancet.
[170] J. Kazura,et al. Helminth- and Bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. , 1999, Journal of immunology.
[171] G. Schoolnik,et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.
[172] S. Dorman,et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection , 1999, Nature Genetics.
[173] M. Torres,et al. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. , 1998, The Journal of infectious diseases.
[174] J. Casanova,et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. , 1998, Science.
[175] F. Deist,et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. , 1998, Science.
[176] S. Kaufmann,et al. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[177] J. Ernst,et al. Macrophage Receptors for Mycobacterium tuberculosis , 1998, Infection and Immunity.
[178] A. Fischer,et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. , 1998, American journal of human genetics.
[179] M. Torres,et al. Cytokine Profiles for Peripheral Blood Lymphocytes from Patients with Active Pulmonary Tuberculosis and Healthy Household Contacts in Response to the 30-Kilodalton Antigen ofMycobacterium tuberculosis , 1998, Infection and Immunity.
[180] J. Mudgett,et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[181] T. Kotsimbos,et al. IFN-gamma and IL-12 are increased in active compared with inactive tuberculosis. , 1997, American journal of respiratory and critical care medicine.
[182] M. Newport,et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.
[183] M. Torres,et al. T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. , 1996, The Journal of infectious diseases.
[184] Z. Toossi,et al. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[185] H. Shiratsuchi,et al. Selective induction of transforming growth factor beta in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis , 1996, Infection and immunity.
[186] W. Rom,et al. Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis , 1995, Molecular medicine.
[187] D. Mitchell,et al. Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. , 1994, American journal of respiratory and critical care medicine.
[188] J. Ellner,et al. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. , 1994, Journal of immunology.
[189] D. James. Granulomatous Infections , 1993 .
[190] D. Mitchison. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.
[191] G. Schoolnik,et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. , 1992, The New England journal of medicine.
[192] M. Horwitz,et al. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. , 1990, Journal of immunology.
[193] Eric N. Miller,et al. HIV‐1 infection , 1990, Neurology.
[194] A. Rattan,et al. Prognostic value of 'C' reactive protein in tuberculosis. , 1989, Indian pediatrics.
[195] S. Vermund,et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.
[196] Comstock Gw. Tuberculosis in twins: a re-analysis of the Prophit survey. , 1978, The American review of respiratory disease.
[197] C. Valentine. Bacillus Calmette Guérin. , 1947, American druggist.
[198] Laurie J. Pencille,et al. The Chest Pain Choice Decision Aid: A Randomized Trial , 2012, Circulation. Cardiovascular quality and outcomes.
[199] A. Liston,et al. Regulatory T Cells , 2011, Methods in Molecular Biology.
[200] Alimuddin Zumla,et al. Biomarkers for tuberculosis disease activity, cure, and relapse. , 2010, The Lancet. Infectious diseases.
[201] A. Aseffa,et al. Immunopathology and Infectious Diseases Compartmentalization of Immune Responses in Human Tuberculosis Few CD 8 Effector T Cells but Elevated Levels of FoxP 3 Regulatory T Cells in the Granulomatous Lesions , 2010 .
[202] N. Sokolenko,et al. Adjunct Immunotherapy of Tuberculosis in Drug-Resistant TB and TB / HIV Co-Infected Patients , 2009 .
[203] E. Bateman,et al. Within-Subject Variability and Boosting of T-Cell IFN-gamma Responses Following Tuberculin Skin Testing , 2009, ATS 2009.
[204] J. Ellner,et al. Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. , 2009, Tuberculosis.
[205] E. Bateman,et al. Rapid Imunodiagnosis of Site-Specific Tuberculosis: Is It Useful in Clinical Practice in South Africa? , 2009, ATS 2009.
[206] P. Polgreen,et al. Mycobacterial Disease Attributable to Tumor Necrosis Factor-α Blockers. Authors' reply , 2008 .
[207] T. Kaisho,et al. Direct extracellular interaction between the early secreted antigen ESAT-6 of Mycobacterium tuberculosis and TLR2 inhibits TLR signaling in macrophages , 2007, Nature Immunology.
[208] Releve Epidemiologique Hebdomadaire. Revised BCG vaccination guidelines for infants at risk for HIV infection. , 2007, Releve epidemiologique hebdomadaire.
[209] Wang Li. Adjuvant Effect of Mycobacterium Vaccae on Treatment of Recurrent Treated Pulmonary Tuberculosis:A Meta-analysis , 2007 .
[210] F. Poccia,et al. Central memory Vgamma9Vdelta2 T lymphocytes primed and expanded by bacillus Calmette-Guérin-infected dendritic cells kill mycobacterial-infected monocytes. , 2007, Journal of immunology.
[211] 藤井 俊策. 子宮 natural killer 細胞の測定意義 , 2006 .
[212] J. Dannenberg. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model , 2006 .
[213] R. Joshi,et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. , 2006, American journal of respiratory and critical care medicine.
[214] H. McShane,et al. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. , 2005, Tuberculosis.
[215] J. Mckinney,et al. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. , 2003, Science.
[216] Alan D. Roberts,et al. MURINE MODEL OF TUBERCULOSIS , 2002 .
[217] J. Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.
[218] K. Chang,et al. Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis. , 2000, Chest.
[219] D. Hom,et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. , 2000, The Journal of infectious diseases.
[220] W. Goebel,et al. Differential expression of , 1999 .
[221] K. Fornataro,et al. Immune control. , 1999, The Body positive.
[222] A. Hill,et al. Host genetic susceptibility to human tuberculosis. , 1998, Novartis Foundation symposium.
[223] Lung Disease,et al. Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance , 1997 .
[224] M. Firlik. [Alveolar macrophages]. , 1985, Polski tygodnik lekarski.
[225] O. Wasz‐Höckert,et al. A bibliography of the complications of BCG vaccination. A comprehensive list of the world literature since the introduction of BCG up to July 1982, supplemented by over 100 personal communications. , 1984, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.
[226] S. Grzybowski,et al. Contacts of cases of active pulmonary tuberculosis. , 1975, Bulletin of the International Union against Tuberculosis.
[227] A. I. Schastnyĭ. [Selective induction]. , 1973, Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova.
[228] J. A. Myers. BCG vaccination. , 1948, American review of tuberculosis.
[229] Alimuddin Zumla,et al. Mycobacterium vaccae ( SRL 172 ) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis : a randomised placebo-controlled trial , 2022 .